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Background: With the goal of reducing exposure to secondhand smoke, the state of Minnesota (MN), enacted a
smoke-free law (i.e., Freedom to Breathe Act) in all workplaces, restaurants, and bars in 2007. This retrospective
cohort study analyzes emergency department (ED) visits in Olmsted County, MN, for chronic obstructive pulmonary
disease (COPD) and asthma over a five-year period to assess changes after enactment of the smoke-free law.
Methods: We calculated the rates of ED visits in Olmsted County, MN, with a primary diagnosis of COPD and
asthma in the five-year period from January 1, 2005 to December 31, 2009. Analyses were performed using
segmented Poisson regression to assess whether ED visit rates declined following enactment of the smoke free law
after adjusting for potential underlying temporal trends in ED visit rates during this time period.
Results: Using segmented Poisson regression analyses, a significant reduction was detected in asthma-related ED
visits (RR 0.814, p < 0.001) but not for COPD-related ED visits following the enactment of the smoke-free law. The
reduction in asthma related ED visits was observed in both adults (RR 0.840, p = 0.015) and children (RR 0.751, p = 0.015).
Conclusions: In Olmsted County, MN, asthma-related ED visits declined significantly after enactment of a smoke-free
law. These results add to the body of literature supporting community health benefits of smoke-free policies in public
environments and their potential to reduce health care costs.
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Tobacco smoke is one of the most common asthma trig-
gers. Asthma may be caused by smoking, and childhood
exposure to secondhand smoke (SHS) increases the risk
for asthma exacerbations [1]. Chronic obstructive pul-
monary disease (COPD) accounts for 73% of smoking-
related conditions among current cigarette smokers and
50% among former smokers [2,3]. Cigarette smoking is
the most important risk factor in the development of
COPD, as well as the most important modifiable risk
factor in reducing the progression and severity of COPD
[4,5]. Reduction in cigarette smoke exposure can reduce* Correspondence: croghan.ivana@mayo.edu
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and asthma [1,5-7].
Protecting the public from exposure to tobacco smoke
is a key component of the World Health Organization
(WHO) Framework Convention on Tobacco Control
[8]. After four decades, worldwide smoke-free policies
and laws are still works in progress [9-12]. Partial or
comprehensive smoke-free workplace laws are in place
in 36 of the 50 United States (US) as well as 92 nations
worldwide [13]. Nearly 50% of the US population is
covered by comprehensive smoke-free regulations and
over 80% are covered by partial smoke-free policies.
Smoke-free policies and laws have been associated with
reduced exposure to SHS and reductions in smoking
prevalence [14-18]. The effects of smoke-free policies
and laws among populations are difficult to accurately
measure due to the number of potential environmentalal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dies, the association between the smoke-free policies and
the reduction of SHS exposure has been unequivocally
demonstrated [19]. Studies have shown a 72% drop in en-
vironmental measures of SHS within one year of smoke-
free workplace law implementation and a median decrease
of 6% in self-reported exposure to SHS [16,17]. In 2009,
there were approximately 2.1 million asthma-related emer-
gency department (ED) visits in the US, which translated
to 69.7 asthma-related visits per 10,000 [20]. In 2010 the
rate for COPD-related ED visits was 1.5 million, which
translated to 72 ED visits per 10,000 [21]. In this study, we
evaluated the impact of the implementation of a state-
wide clean indoor air law in 2007 (i.e., Freedom to Breathe
Act) on the frequency of ED visits for asthma and COPD
[12] within Olmsted County, Minnesota (MN).
Methods
Study setting
The 2013 population estimate of Olmsted County, lo-
cated in southeastern MN, was 147,066 (86.5% white,
51.1% female) [22]. Within this county, two providers
(Mayo Clinic and Olmsted Medical Center) deliver
nearly all medical care and ED services to county resi-
dents. The Rochester Epidemiology Project (REP) [23]
allows the linkage of medical records and retrieval of
diagnoses and procedures from all sources of care in
Olmsted County. This provides a unique infrastructure
to analyse disease occurrence and outcomes at the popu-
lation level. Potential cases identified through the REP
can then be validated by applying standardized methods
appropriate for each disease entity [24].
Ascertainment of asthma and COPD ED visits
The MN smoke-free law that was passed on May 16,
2007, and enacted on October 1, 2007, included all
workplaces (including bars and restaurants) [12]. The
data collected for this review included all ED visits in
Olmsted County, MN, from January 1, 2005, through
December 31, 2009, providing a window of approxi-
mately two years before and after the effective date of
the smoke-free law.Table 1 Patient characteristics
Characteristic COPD
n = 5293
Age, y, median (25th, 75th) 75 (64, 82)
Sex
Female, n (%) 2551 (48.2)
Male, n (%) 2742 (51.8)
Abbreviation: COPD chronic obstructive pulmonary disease.All ED visits with the primary diagnosis of COPD
(International Classification of Diseases, Ninth Revision
codes 491–492 and 494–496) or asthma (International
Classification of Diseases, Ninth Revision code 493) were
captured. When multiple ED visits occurred for a single
person, all visits were counted since our focus was to as-
sess changes in ED utilization over time for a defined
geographic population.
Statistical analysis
In order to account for potential underlying temporal
trends in ED visit rates, analyses were performed using
segmented Poisson regression [25]. For all Poisson regres-
sion analyses, the ED visit counts for each period-, age-,
and sex-combination were used as the unit of observation,
with the period-, age-, and sex-specific population counts
used as offsets. Since many work places transitioned to
smoke-free environments between the passage of the law
(5/16/2007) and its implementation (10/01/2007), this
calendar period was considered a transition period. Given
the limited number of monthly counts during this tran-
sition period, the visit counts for May 2007 through
September 2007 were excluded rather than modeled as a
separate segment. The models included terms to assess
for a linear trend prior to passage of the smoke-free law, a
step-change with the implementation of the law, and the
change in trend after implementation. Due to the broad
age range of patients with asthma-related ED visits, ana-
lyses were performed overall and separately for adults
(≥18 years of age) and children (<18 years of age). Ana-
lyses were performed using SAS software (SAS version
9.3; SAS Institute Inc., Cary, NC).
All aspects of the study were approved by the Mayo




During the 5-year study period (January 1, 2005 through
December 31, 2009), a total of 5,293 ED visits occurred
with a primary diagnosis of COPD and 5,906 ED visits
with a primary diagnosis of asthma (Table 1).Asthma
Overall Adults Children
n = 5906 n = 4375 n = 1531
37 (17, 57) 47 (33, 65) 6 (3, 11)
3619 (61.3) 2994 (68.4) 625 (40.8)
2287 (38.7) 1381 (31.6) 906 (59.2)
Table 2 Segmented poisson regression results*
Monthly trend before
law was passed (β1)
Step change when
law took effect (β2)
Change in trend after
law took effect (β3)
Monthly trend after
law took effect (β1 + β3)
COPD
β (SE) −0.002 (0.002) −0.091 (0.065) −0.004 (0.004) −0.006 (0.003)
RR (95% CI) 0.998 (0.993, 1.002) 0.913 (0.804, 1.036) 0.994 (0.989, 0.999)
p value 0.331 0.158 0.313 0.028
Asthma
Overall
β (SE) +0.003 (0.002) −0.206 (0.061) −0.002 (0.003) +0.000 (0.003)
RR (95% CI) 1.003 (0.998, 1.007) 0.814 (0.722, 0.918) 1.000 (0.995, 1.005)
p value 0.236 <0.001 0.502 0.876
Adults
β (SE) −0.000 (0.003) −0.175 (0.072) +0.002 (0.004) +0.002 (0.003)
RR (95% CI) 1.000 (0.994, 1.005) 0.840 (0.729, 0.966) 1.002 (0.996, 1.008)
p value 0.922 0.015 0.611 0.552
Children
β (SE) +0.011 (0.004) −0.287 (0.118) −0.015 (0.007) −0.004 (0.005)
RR (95% CI) 1.011 (1.002, 1.020) 0.751 (0.595, 0.947) 0.996 (0.986, 1.006)
p value 0.015 0.015 0.027 0.424
*The segmented Poisson regression model adjusted for age and sex provides estimates for the trend in ED visits over time prior to the law being passed (β1), the step change
after the law took effect (β2) and the change in trend after the law took effect (β3). The sum of β1 and β3 corresponds to the trend over time after the law took effect.
Abbreviation: COPD chronic obstructive pulmonary disease.
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The results of the segmented Poisson regression analyses
are summarized in Table 2 and Figures 1, 2, 3 and 4. For
COPD, the implementation of the smoke-free law was not
found to be associated with a significant step change in
ED visit rates (p = 0.158) or with a change in the trend
(p = 0.313; Figure 1). There was evidence that the imple-
mentation of the smoke-free law was associated with a
downward step change in ED visits for asthma (RR = 0.814,
95% CI 0.722 to 0.966; p < 0.001; Figure 2). When the ana-
lysis of ED visits for asthma was restricted to adults a simi-




























Figure 1 ED visit rates for COPD before and after smoke-free law. Visi
The vertical dashed lines indicate the time period between when the law w
predicted rates from segmented Poisson regression.CI 0.729 to 0.966; p = 0.015; Figure 3). For children, in
addition to a downward step change with the implementa-
tion of the smoke-free law (RR = 0.751, 95% CI 0.595 to
0.947; p = 0.015), there was a significant (p = 0.027) change
in the trend over time, such that the significant (p = 0.015)
increasing trend observed prior to the smoke-free law
being passed was no longer present after the law was
enacted (p = 0.424; Figure 4).
Discussion
In this study, we observed a reduction in asthma-related




t rates are presented monthly from 1/1/2005 through 12/31/2009.






























Figure 2 ED visit rates for asthma before and after smoke-free law. Visit rates are presented monthly from 1/1/2005 through 12/31/2009.
The vertical dashed lines indicate the time period between when the law was passed and when the law took effect. Solid lines represent the
predicted rates from segmented Poisson regression.
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investigations have evaluated the association between
smoke-free laws and asthma incidence, symptoms, hos-
pitalizations, and asthma-related ED visits [14,15,26,27]
with similar findings. Our findings are in keeping with a
number of studies demonstrating the health benefits of
smoke-free indoor air laws, particularly with regard to
asthma. Investigators in Kentucky evaluated ED visits
for asthma from four different hospitals, comparing rates
before and after implementation of a smoke-free law. A
22% reduction in asthma-related ED visits after imple-
mentation of the smoke free law was observed [26]. The
percentage reduction in asthma-related ED visits is simi-
lar to our results. In slight contrast, a study in England
evaluating the impact of smoke-free laws on emergency
room admissions observed only a 4.9% reduction in
asthma-related ED visits after implementation of the
smoke-free laws [28]. In a multi-state study, hospital





























Figure 3 Adult ED visit rates for asthma before and after smoke-free
2009. The vertical dashed lines indicate the time period between when the
the predicted rates from segmented Poisson regression.states with strong smoke-free laws and 5 with weak or
no smoke-free laws. A significant reduction in hospital
discharges for asthma was observed in states with strong
smoke-free laws [14]. Additionally, a recent review of 45
studies focusing on 33 smoke-free laws found a 24% re-
duction in overall respiratory disease hospitalizations
and deaths [29]. This study, with a median follow-up of
two years after smoke-free law implementation, ob-
served that the risk of hospitalization and death from
tobacco-caused disease does not change with longer
follow-up, suggesting that risk reductions will likely be
sustained over time [29]. An Arizona study comparing
hospital admissions between counties with and without
smoke-free policies for the four major tobacco-related
diseases (acute myocardial infarction, angina, stroke,
and asthma) found a reduction in hospital admissions
for these diseases among those counties with a smoke-
free policy; notably, asthma admissions were reduced by




law. Visit rates are presented monthly from 1/1/2005 through 12/31/

































Figure 4 Child ED visit rates for asthma before and after smoke-free law. Visit rates are presented monthly from 1/1/2005 through
12/31/2009. The vertical dashed lines indicate the time period between when the law was passed and when the law took effect. Solid lines
represent the predicted rates from segmented Poisson regression.
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wise fashion, an association with asthma incidence has
not always been found to be consistent between steps.
Two studies evaluated more than two periods during
smoke-free policy enactment and found little to no asso-
ciation. Investigators in Toronto, Canada who reviewed
multiple periods during smoke-free policy enactment
and implementation found a large decrease in respi-
ratory conditions overall when the smoke-free law was
implemented for restaurant settings, but found no sub-
sequent change when the law was extended to other in-
door settings [31]. A study conducted in Geneva looked
at hospital admissions in one hospital during four differ-
ing time periods in the smoke-free law enactment and
implementation process; and although a similar analysis
(adjusted Poisson Regression) was used, they found the
reverse of our findings. In their study, they found a re-
duction in COPD hospital admissions but not in asthma
admissions [32].
Data concerning the impact of the smoke-free policy
upon ED visits by asthmatic youth are more robust. A
study in Ireland evaluating the impact of the nationwide
smoke-free policy showed a larger reduction in asthma-
related ED visits (RR = 0.60) for the younger age group
compared to overall asthma-related ED visits (RR = 0.85)
[33]. This is consistent with our study findings of a
larger reduction in asthma-related ED visits in children
(RR = 0.75), compared to overall asthma-related ED
visits (RR = 0.81). In another study in England smoke-
free policies were temporally-related to a 12.3% reduc-
tion in childhood asthma-related ED visits [27]. A study
in the US, which reviewed data among youth from the
National Health and Nutrition Examination Survey
(NHNES) between 1999 and 2006, observed a significant
reduction (OR = 0.66) in asthmatic symptoms related to
the implementation of smoke-free laws [34]. In Scotland,a trend for increasing childhood asthma-related ED
visits (+5.2% per year) was observed prior to smoke-free
law implementation, but a significant decrease in child-
hood asthma-related ED visits (−18.2% per year) was
found after the law was implemented, yielding a net re-
duction of 13% per year following the smoke-free policy
implementation [35]. Among children in our current
study, we found that an upward trend in ED visit rates
(+1.1% per month) for asthma prior to the passage of
the smoke-free law was reversed, resulting in a down-
ward trend (−0.4% per month) following the implemen-
tation of the law.
The findings that asthma-related ED visits were sig-
nificantly reduced after the smoke-free law implemen-
tation, but the COPD-related visits were not significantly
reduced, is not surprising. The lack of findings with
COPD-related visits confirms findings from a recent
meta-analysis [29]. Typically COPD is associated with
irreversible or minimally reversible airway obstruction,
unlike the bronchospasms in asthma, which can be
severe but may be completely reversible. Exposure to
triggers such as SHS may precipitate acute broncho-
spasms in asthmatics and is more likely to increase re-
spiratory symptoms but not acute bronchospasms in
people with COPD. Acute exacerbations of asthma often
require emergency treatment or hospitalization to re-
verse. In communities with strong smoke-free laws, the
changes in COPD-related hospital and ED admissions
may be seen 12 months or more after implementation of
the law [36]. This likely reflects the slower improvement
seen in COPD symptoms and exacerbations as SHS
smoke exposure declines. This may also explain the vari-
able effects that are noted in studies of smoke-free laws
on COPD adverse events. Investigators in Ireland, using
time series analysis, evaluated the impact of the nation-
wide smoke-free law and found an effect only for COPD
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of hospital discharge rates in Texas found a reduction for
COPD hospital discharges only for white patients after
implementation of the smoke-free law [38]. The greatest
impact of smoke-free laws on COPD may be the effect
they have on encouraging smokers to quit smoking, thus
reducing the risk of COPD progression. This impact
would be seen over the longer term and may be variable
among the affected populations, consistent with the em-
pirical data from population-based studies.
Our finding of decreased asthma-related ED visits
following implementation of a statewide smoke-free law
is biologically plausible and consistent with the known
causal relationship between cigarette smoke exposure
and exacerbation of pulmonary disease symptoms [39]
as well as with previous observations of the relationship
between smoke-free policies and reductions in SHS expos-
ure and respiratory symptoms. The WHO estimated that
smoke-free policies are associated with 40% (widespread)
to 80%-90% (in high exposure setting) reductions in SHS
exposure [40]. This report has been supported by a sys-
tematic review of over 50 studies addressing the role of
the smoke-free policies on exposure to SHS [16]. In this
systematic review, the studies addressing the role of SHS
exposure consistently found a reduction of SHS in public
places (workplace, restaurants, and bars) of about 72%
within one year of a smoke-free law implementation [16].
This review also reported reductions in both reported re-
spiratory and sensory irritation symptoms after smoke-
free law implementation in 10 studies [16]. These sensory
symptoms included wheezing or whistling in chest; short-
ness of breath; cough; phlegm; red, teary, or irritated eyes;
runny nose or sneezing; and sore or scratchy throat. An
additional study, not included in the prior referenced
review, is a cross-sectional telephone survey of 382 non-
smokers in the workplace, which showed a positive
dose–response relationship between exposure to SHS and
increased reports of respiratory ailments [41]. Another
study, which evaluated the impact of workplace and pub
smoke-free laws in Ireland, collected air samples and con-
ducted pulmonary function tests among 81 employees of
42 pubs before, and 1 year after, the law was implemented
[42]. Using particulate matter, benzene concentration, ex-
pired air carbon monoxide, and salivary cotinine, the re-
searchers found a 90% reduction to SHS exposure (i.e.,
83% reduction in particulate matter 2.5 μm or smaller, an
80% reduction in benzene concentration, a 79% reduction
in expired air carbon monoxide, and an 81% reduction in
salivary cotinine), a significant improvement in respiratory
function, and a decrease in other respiratory symptoms in
nonsmokers after implementation of the law [42].
Our study has several limitations. First, we did not
measure actual SHS exposure in different environments
around the community. Second, our study data waslimited only to ED visits which were for the most part,
ambulatory and did not include hospital admissions for
the local hospitals. Third, other tobacco control efforts
were occurring during the study period, which could
have contributed to the decrease in smoking prevalence
and to reductions in SHS exposure. For example, from
1999 through 2010, the per capita cigarette sales in MN
declined by 40% and smoke-free homes increased from
64.5% (1999) to 87.2% (2010) [43]. Other activities
included a marketing campaign for the state tobacco
quitline and local clinic tobacco treatment services and
a 2004–2007 mass media campaign focused on the
hazards of SHS. Despite these limitations, the data pre-
sented does parallel the 22% postban reduction of re-
spiratory ED visits associated with the smoke-free law of
other geographic locations [26,30,31].
Conclusion
Following the enactment of a smoke-free workplace law
we observed a reduction in asthma-related ED visits for
both adults and children. This finding underscores the
importance of comprehensive smoke-free laws and poli-
cies for improving public health and reducing health
care costs. Communities need to continue to advocate
for smoke-free laws and policies in order to reduce the
burden of disease caused by SHS.
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